Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

Abstract: Provided are an oncolytic heterologous recombinant Newcastle disease virus (NDV), preparation method and application thereof. The heterologous recombinant NDV can express alpha (1,3) galactosyltransferase (?1,3GT). The ?1,3GT is the protein represented by the flowing B1) and B2): B1) the protein has an amino acid sequence of SEQ ID No.1; and B2) the protein is derived from B1) and has a function of ?1,3GT obtained by substituting and/or deleting and/or adding one or more amino acid residue(s) in the amino acid sequence represented by SEQ ID No.1. The recombination NDV can be used for tumor treatment.

Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.

Abstract: The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein.

Abstract: A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (CPAC) using insulator-dielectrophorsis (i-DEP)-based devices. The ionized gas uniquely forms more and varied chaperone proteins and chaperone protein-antigen complexes (CPAC) than prior art mechanical, chemical, electric or other lysing techniques. These CPAC generated by the ionized gas lysis and separated by i-DEP are electrospray-encapsulated by a biodegradeable polymer at the nano particle level to further enhance these personalized vaccines for accelerated immune system uptake. For the first time, sterile eradication of infectious pathogens and cancer (known or unknown to exist in the host) can be accomplished with multiple personalized vaccine treatments.

Abstract: A method for the creation of a personalized vaccine. Multiple and varied antigens in conjunction with heat shock proteins (and other protein chaperones) are generated by ionized gas lysing coupled with the separation, concentration, and purification of these chaperone protein-antigen complexes (CPAC) using insulator-dielectrophorsis (i-DEP)-based devices. The ionized gas uniquely forms more and varied chaperone proteins and chaperone protein-antigen complexes (CPAC) than prior art mechanical, chemical, electric or other lysing techniques. These CPAC generated by the ionized gas lysis and separated by i-DEP are electrospray-encapsulated by a biodegradeable polymer at the nano particle level to further enhance these personalized vaccines for accelerated immune system uptake. For the first time, sterile eradication of infectious pathogens and cancer (known or unknown to exist in the host) can be accomplished with multiple personalized vaccine treatments.

Abstract: Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human tau(pS422) and an anti-blood brain barrier receptor/hapten bispecific antibody.

Abstract: Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.

Abstract: The present disclosure relates to liposomal delivery vehicles comprising magnetic particles and their use in modifying stem cells for delivery to target sites such as neuronal tissues.

Abstract: This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium. The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.

Abstract: A liquid pharmaceutical composition having an anti-TNF? antibody, a buffer, a stabilizer, and a surfactant.

Abstract: The present invention provides a composition comprising (i) a mixed metal compound containing at least one trivalent metal selected from iron (III) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, (ii) xanthan gum (iii) at least one of (a) polyvinyl pyrrolidone (b) locust bean gum (c) methyl cellulose wherein the composition has been irradiated with ionising radiation in an amount of at least 4kGy.

Abstract: Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders. The compositions are especially suitable for localized delivery and may allow for intratamoral delivery and treatment of cancers or stimulation of an immune response to a co-administered antigen.

Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.

Abstract: The present invention discloses doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin.

Abstract: The present invention relates to anti-FGFR2 and FGFR4 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

Abstract: The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.

Abstract: The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.

Abstract: A filamentous plant virus carrier comprising a filamentous plant virus particle that has been modified to carry an imaging agent or cytotoxic compound is described. The filamentous plant virus carrier can be used in a method of targeting cancer cells and tissue by administering it to a subject. Cancer tissue targeted by the filamentous plant virus carrier can be imaged using an imaging agent, or treated using a cytotoxic compound.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: A compound comprising a cyclodextrin and a monoalkoxy polyethylene glycol linked thereto through an ether bond (a “pegylated cyclodextrin”) is disclosed, as are drug delivery vehicles and pharmaceutical formulations including the same, and methods for making the compound and the drug delivery vehicle and for delivering the drug to a patient in need thereof. The method of making includes the steps of creating either a tosylated monoalkoxy polyethylene glycol or a tosylated cyclodextrin, and either reacting the tosylated monoalkoxy polyethylene glycol with a deprotonated cyclodextrin, or reacting the tosylated cyclodextrin with a deprotonated monoalkoxy polyethylene glycol. The present pegylated cyclodextrin readily forms an inclusion compound with certain drugs to protect the drug against adverse interactions with mucin (e.g., in a mucus membrane).

Abstract: Methods of identifying circulating macrophage-tumor cell fusion hybrids from a subject, methods of screening test compounds for inhibition of activity of in vitro and in vivo derived macrophage-tumor cell fusion hybrids, and methods of assessing the probability of survival of a human subject with pancreatic cancer past one year are disclosed.

Abstract: Disclosed herein are nanoparticles for diagnosis or treatment of tumors. The nanoparticles include: (a) a core including a Prussian blue dye; and (b) a shell obtained by partially or completely coating a surface of the Prussian blue core with albumin, thereby diagnosing a tumor by a nuclear magnetic resonance imaging apparatus and a near-infrared fluorescence imaging apparatus and necrotizing a tumor by a combined photothermal-photodynamic effect.

Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.

Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to automated methods for the preparation and purification of 18F-labelled tau imaging radiotracers. Also provided are interchangeable cassettes useful in the methods, and the use of automated synthesizers and cassettes in the methods.

Abstract: Disclosed herein are globular nanostructures having a hydrodynamic diameter (Dh) of 8-100 nm comprising a central part and a peripheral part, wherein said central part has a calculated diameter (Dc) of 6-90 nm and said peripheral part has an estimated thickness (Tp) so that Dh=Dc+2Tp, wherein said central part comprises: (i) a crosslinked polymeric framework comprising monomer residues wherein at least 30% by number of the monomer residues have crosslinked thereby forming the crosslinked polymeric framework and/or (ii) a branched polymeric framework comprising monomer residues wherein the number of branch points is at least 30% of the number of monomer residues, wherein said central part comprises chelating groups of which at least 4 allow chelation of at least one multiply charged cation, wherein said chelating groups are independently selected from the group consisting of —COOR1, —P?O(OR1)(OR2), and —S(?O)2OR1, wherein R1 and R2 are independently selected from the group consisting of a negative charge, H, a

Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.

Abstract: A method for processing a cosmetic product with high hydrostatic pressures by applying a pressure P to the cosmetic product, with a continuous or cyclic application mode MA. The method is performed using at least one, and preferably all, of the following parameters: total application time t of pressure P of between 2 and 60 minutes, a pressure P of between 200 MPa and 600 MPa, a pressure application rate, for a compression VA, of between 1 and 5 QMPa/s, a decompression rate VAD of between 1 and 50 MPa/s, when the application mode is cyclic, a latency time tlat applied before the first cycle and/or between certain cycles and/or between each cycle, and an initial temperature of between ?10° C. and 40° C. Also, the cosmetic product obtained and a device for implementing. The method can be used to deactivate microorganism(s) in pharmaceutical product or to modify the texture of the same.

Abstract: A sterilizer for toothbrushes, puffs for cosmetic use and cosmetic brushes that dehydrates and sterilizes toothbrushes, puffs for cosmetic use and cosmetic brushes en bloc with ease and includes a housing 10, a cover 20 that is put on and removed from the housing from above, a dehydrating sterilizer member 30 that protrudes vertically upwards from the center of the bottom surface of the housing 10, a lower holder member 40 that is inserted in the housing 10 and has a insertion hole 44 through which the dehydrating sterilizer member 30 is inserted and hold cups 45 that accept toothbrushes and cosmetic brushes, an upper holder member 50 that is placed on the upper portion of the lower holder member 40 and a holder 60 that holds a puff for cosmetic use.

Abstract: A method for sterilizing a solid substance including contacting a solid substance with a Fenton reaction catalyst, the Fenton reaction catalyst including a reaction product, wherein the reaction product includes divalent iron, wherein the reaction product is obtained by providing a feedstock for supplying a component having a reduction effect, the feedstock being selected from the group consisting of (i) coffee grounds after extraction of coffee and (ii) tea dregs, the feedstock being a dried product, and mixing the feedstock with an iron ion-supplying source containing divalent or trivalent iron, and then adding water, the source being at least one substance selected from the group consisting of iron (II) chloride, iron (III) chloride, iron (II) nitrate, iron (III) nitrate, iron (II) sulfate, iron (III) sulfate, iron (II) hydroxide, iron (III) hydroxide, iron (III) oxide; a heme iron; a product obtained by dissolving iron ore, metallic iron or iron (III) oxide-rich red soil with an acid; and rust, and wherei

Abstract: An allergen reducing composition capable of reducing allergens such as mites and cedar pollen and causes less coloring of an allergen reduction target; a spray agent using the allergen reducing composition; a surface treatment agent using the allergen reducing composition; an allergen reducing method; an allergen reducing textile structure; and an allergen reducing architectural interior material. The allergen reducing composition contains: (A) one or more compounds selected from zinc salts and copper salts; and (B) one or more compounds selected from rare earth salts. The spray agent or the surface treatment agent contains the allergen reducing composition and water or a water-soluble solvent. An allergen reducing method involves using the above-mentioned allergen reducing composition in an environment where allergens are present. The textile structure is a textile structure processed by the allergen reducing composition.

Abstract: The present invention comprises a composition comprising a combination of hexanal, 3,7-dimethylocta-2,6-dienal, and 2,6-dimethyl-5-heptenal wherein: hexanal is in an amount from 0.1 to 4% by weight of the total weight of the composition; 3,7-dimethylocta-2,6-dienal is in an amount from 5 to 25% by weight of the total weight of the composition; and 2,6-dimethyl-5-heptenal is in an amount from 1 to 8% by weight of the total weight of the composition; to articles containing the composition; as well as its use for counteracting malodours and a process for counteracting malodours.

Abstract: A scented article including: a fluid pervious pouch enclosing a chamber; and a plurality of water soluble particles contained in the chamber; wherein the pouch comprises a fluid pervious substrate having an apparent opening size according to ASTM D4751-12 smaller than about 1000 ?m; wherein the particles comprise a carrier and a perfume; wherein the particles have an individual mass between about 0.1 mg to about 10 g; and where the plurality of particles has a mass between about 5 g and about 100 g.

Abstract: Methods and apparatus for vaporizing liquid into the surrounding environment, including directing liquid from a liquid source through an inverse-opal wicking structure to a vaporization port where the vaporization port is formed by a through-hole in a structure connecting a first side of the structure to a second side, with all dimensions ranging from 10 um to 300 um, that is in fluid communication with the liquid source and the surrounding environment so that fluid is transported through the vaporization port between the first and the second side. The methods and apparatus includes plurality of heating elements that may be individually and/or selectively addressable by at least three electrode leads.

Abstract: A scented article including: a fluid pervious pouch enclosing a chamber, wherein the pouch comprises a bond that at least partially defines the chamber; a plurality of particles contained in the chamber, wherein the particles comprise perfume; wherein the pouch comprises a loop or aperture sized and dimensioned to fit onto a clothing hanger.

Abstract: A volatile substance delivery system includes a volatile substance container to contain a volatile substance, an optional absorbent and collapsible element disposed within the container to reduce presence of undesired air during manufacture of the device, an outlet to deliver a volume of the volatile substance from the volatile substance container to an ambient environment, and a manual screw pump to reduce volume (or sometimes, just increase pressure) within the volatile substance container and promote the delivery of the volatile substance from the volatile substance container.

Abstract: Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds.

Abstract: Provided herein are methods for treating, adhering, or sealing biological tissue with a material, such as a hydrogel, that may include phyllosilicate nanoplatelets. The phyllosilicate nanoplatelets can have a high aspect ratio, a low aspect ratio, or be a mixture of high aspect ratio and low aspect ratio nanoplatelets. Drug releasing compositions and kits also are provided herein.

Abstract: Mono- and multi-layered implants include at least one porous layer made from a freeze dried aqueous solution containing chitosan, the solution having a pH of less than about 5.

Abstract: Implantable matrices are provided that include at least one therapeutic agent having hemostatic and antimicrobial activity. The implantable matrices are configured to be implanted into a hone defect. The implantable matrices aid in reducing operative and post-operative bleeding and inhibiting microbial growth. In some embodiments, the matrices provided include therapeutic agent(s) having hemostatic and antimicrobial activity that do not compromise the bioactivity of the matrix to induce or permit new tissue growth.

Abstract: Provided herein are compositions comprising a composite of peptide amphiphiles and biocompatible particles and methods of use thereof for treatment of bone and/or tissue defects. In particular, compositions comprise a slurry paste of a peptide amphiphile nanofiber solution mixed with solid biocompatible particles, and find use in tissue/bone regeneration, growth factor delivery, and/or cell delivery.

Abstract: There is provided a method for producing an artificial retina in which an organic dye compound that induces a receptor potential responding to photostimulation is fixed on a polymer sheet substrate, comprising a bonding step of immersing the substrate in a solution containing the organic dye compound to chemically bond the organic dye compound to the substrate; a first washing step of washing with water the substrate to which the organic dye compound has been chemically bonded; and a second washing step of, after the first washing step, washing with an organic solvent the substrate to which the organic dye compound has been chemically bonded. Thus, there can be provided an artificial retina which has excellent mechanical properties such as elongation at break and good biocompatibility, and is capable of inducing a receptor potential responding to photostimulation with high sensitivity.

Abstract: The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making said compositions, and methods of utilizing the same.

Abstract: A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy includes magnesium, between 7 and 8 weight percent aluminum, between 0.4 and 0.8 weight percent zinc, and between 0.05 and 0.8 weight percent manganese.

Abstract: A method for making a device including a polyisobutylene-polyurethane block copolymer. The method includes polymerizing a polyisobutylene diol, a diisocyanate, and a chain extender within a solvent system to form a polyisobutylene-polyurethane block copolymer solution, depositing the polyisobutylene-polyurethane block copolymer solution onto at least a portion of the device, and evaporating the solvent system from the deposited polyisobutylene-polyurethane block copolymer solution.

Abstract: The present disclosure provides a hydrogel composition including: a hydrogel having a structure represented by Formula (I) or Formula (II) shown as follows: A-B-BOX-B-A, Formula (I); B-A-B-(BOX-BAB)n-BOX-B-A-B, Formula (II), wherein, A is a hydrophilic polyethylene glycol polymer, B is a hydrophobic polyester polymer, BOX is a bifunctional group monomer of 2,2?-Bis(2-oxazoline) for coupling di-block of A-B or tri-block of B-A-B, and n is an integer greater than or equal to 0; and an anti-adhesion additive, wherein the anti-adhesion additive comprises a carbohydrate, a nitrogen-containing cyclic compound, a polymer or a combination thereof.

Abstract: Various forms of anti-clog suction tips apparatus are disclosed. An exemplary anti-clog suction tip apparatus includes a suction tip assembly having a suction tip with a suction opening at a first end thereof for removing debris through suction, a hose attachment portion for attaching the suction tip assembly to a suction source, and an ejection wire channel. The apparatus further includes an ejection wire assembly having an ejection wire extending within the channel and an ejection button integral with or connected to the ejection wire. Applying a force to the ejection button advances the ejection wire through the channel such that an end portion of the ejection wire enters the suction tip and dislodges debris clogging the suction tip. The ejection wire may include an enlarged end portion such as, for example a ball tip. One or more of the components of the apparatus may be single-use and disposable.

Abstract: Fluid collection systems having a canister, a lid, and a liner assembly are described. The liner assembly may include a liner and a fitment assembly. The fitment assembly may be connected to the liner by a gland. The fitment assembly may be held in place by at least one of any number of features, including a bracket or other fitment support connected to the canister and/or the lid, supports integrated into the fitment itself, a snapping mechanism, or a notch in one or more of the canister and the lid that supports the fitment.